NRTX-1001
Drug-resistant Focal Epilepsy (Mesial Temporal Lobe Epilepsy)
Key Facts
About Neurona Therapeutics
Neurona Therapeutics is a pioneering cell therapy company focused on repairing dysfunctional neural circuits underlying chronic neurological diseases. Its core technology involves creating off-the-shelf, allogeneic neural cell therapies, with its lead program, NRTX-1001, advancing toward a pivotal Phase 3 trial in focal epilepsy in 2026. Founded in 2008 and based in South San Francisco, the private company is positioned at the forefront of regenerative neurology, targeting large, underserved patient populations with high unmet need. Its approach represents a paradigm shift from symptom management to potential one-time, disease-modifying treatments.
View full company profileAbout Neurona Therapeutics
Neurona Therapeutics is a pioneering cell therapy company focused on repairing dysfunctional neural circuits underlying chronic neurological diseases. Its core technology involves creating off-the-shelf, allogeneic neural cell therapies, with its lead program, NRTX-1001, advancing toward a pivotal Phase 3 trial in focal epilepsy in 2026. Founded in 2008 and based in South San Francisco, the private company is positioned at the forefront of regenerative neurology, targeting large, underserved patient populations with high unmet need. Its approach represents a paradigm shift from symptom management to potential one-time, disease-modifying treatments.
View full company profile